Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
54,567,681
-
Share change
-
+16,696,080
-
Total reported value
-
$421,799,729
-
Put/Call ratio
-
280%
-
Price per share
-
$7.73
-
Number of holders
-
124
-
Value change
-
+$130,729,085
-
Number of buys
-
71
-
Number of sells
-
52
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2021
As of 31 Mar 2021 CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) had 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 54,567,681 shares of stock of the company.
Largest 10 holders included Point72 Asset Management, L.P., BVF INC/IL, BlackRock Inc., VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., STATE STREET CORP, VICTORY CAPITAL MANAGEMENT INC, PERCEPTIVE ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, and RTW INVESTMENTS, LP.
This table shows 124 institutional shareholders of the security as of 31 Mar 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.